The present technology provides a method for diagnosing Alzheimer＇s disease, including the following steps: detecting a blood sample taken from a human subject suspected of having Alzheimer＇s disease,the biomarker level is selected from G72 protein level, SLC7A11 mRNA expression level,a combination of the two,compared with a preset standard, wherein if the detected biomarker level in the blood sample is higher than the preset standard, the Individual humans are thought to have Alzheimer＇s disease.

Current research on biomarkers of Alzheimer＇s disease has focused on known pathological substrates, such as amyloid plaquesneurofibrillary tangles, but has not yet produced a usefuldefinitive diagnostic method. The current technology is based on new mechanisms of DAAO activator (DAOA,named G72)cystine/glutamate antiporter system xc-. The combination of G72SLC7A11 (xCT) ΔCT determined a favorable AUC between patients with Alzheimer＇s diseasehealthy controls. There has been no similar product on the market.

The number of patients suffering from Alzheimer＇s disease is increasing rapidly around the world. However, there is still a lack of simpleaccurate diagnostic tools, therefore hampering its early diagnosistreatmentconsequently increasing family burdensocial cost. The current technology uses peripheral blood to preciselyeasily diagnose Alzheimer＇s disease. Due to its fast, easy,low-invasive advantage, it can not only generate huge industrial value but thereafter also reduce the social cost. Our technique has obtained domesticinternational patents.

1.欲媒合之產業領域：生技醫藥。2.欲媒合項目：技術合作、技術轉移、生產製造、投資合作。